Valiant Laboratories LimitedVALIANTLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data

₹134.65

MCap ₹731 Cr · P/E 46.0

Valiant Laboratories Limited — Stock analysis & AI research Valiant Laboratories Limited — Multibagger AI analysis Valiant Laboratories Limited — Seasonality — best & worst months Valiant Laboratories Limited — Technical setup — score, trend, support & resistance Valiant Laboratories Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹115 Cr

Sales · Jun 2026

+145.6% YoY

₹29 Cr

Operating Profit · Jun 2026

+1108.7% YoY

25.2%

OPM % · Jun 2026

+394.1% YoY

₹21 Cr

Net Profit · Jun 2026

+1053.3% YoY

₹3.88

EPS · Jun 2026

+823.8% YoY

📝 Valiant Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Valiant Laboratories Limited reported revenue of ₹115 crore for the quarter ended June 2026 (Q1 FY27), up 145.6% from ₹47 crore in the same quarter last year, and up 25.0% sequentially over the March 2026 quarter.

Net profit rose 1053.3% year-on-year to ₹21 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹3.88.

Operating profit stood at ₹29 crore — an operating margin (OPM) of 25.2%, compared with 5.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Valiant Laboratories Limited posted revenue of ₹237 crore, a growth of 78.0% over FY25, with a net loss of ₹3 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹306 crore with a net profit of ₹16 crore.

Valuation snapshot

At the current price of ₹134.65, VALIANTLAB has a market capitalisation of ₹731 crore and a trailing P/E of about 46.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 74.94%, foreign institutional investors (FIIs) 0.07%, domestic institutional investors (DIIs) 0.08%, public shareholders 24.91% of Valiant Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹731 Cr

Current Price ?

₹134.7

P/E ?

45.98above ind

Industry P/E ?

37.20

P/B ?

2.35

P/S ?

2.39

P/FCF ?

-16.25

Enterprise Value ?

₹777 Cr

EV/EBITDA ?

23.55

PEG ?

N/A

Earnings Yield ?

3.2%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹306 Cr

OPM ?

10.8%

Profit after tax (TTM) ?

₹16 Cr

EPS (TTM) ?

₹2.93

ROCE ?

1.0%

ROE ?

5.1%

ROA ?

3.4%

Growth

Sales — latest qtr ?

₹115 Cr

PAT — latest qtr ?

₹21 Cr

YoY qtr sales growth ?

145.6%

YoY qtr profit growth ?

1,053.3%

Sales growth (3y) ?

-11%

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹46 Cr

Debt to Equity ?

0.15

Interest Coverage ?

0.2

Current Ratio ?

N/A

Ownership

Promoter holding ?

74.94%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

112.2%

Return 6 months ?

96.9%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	90	51	60	41	31	19	21	35	58	47	46	52	92	115	+145.6%	+25.0%
Operating Profit	9	4	-1	-6	-5	-2	-7	1	4	2	0	-1	5	29	+1108.7%	+502.9%
Other Income	2	2	3	2	2	3	3	2	-2	1	1	1	0	1	+52.6%	+488.2%
Interest	0	0	0	0	0	0	0	0	0	0	0	1	1	1	+1264.3%	-1.0%
Depreciation	0	0	0	0	1	1	1	1	1	1	1	2	3	3	+463.3%	+2.4%
Profit Before Tax	10	6	1	-5	-3	-0	-4	2	1	2	0	-3	1	26	+961.8%	+2400.0%
Net Profit	8	4	1	-4	-1	-1	-5	2	1	2	0	-7	2	21	+1053.3%	+1093.2%
EPS	1.92	1.05	0.19	-0.81	-0.23	-0.12	-0.87	0.54	0.13	0.42	0.04	-1.30	0.32	3.88	+823.8%	+1112.5%
OPM %	9.6%	7.4%	-2.3%	-15.6%	-14.8%	-12.6%	-31.4%	1.8%	6.6%	5.1%	0.2%	-1.7%	5.2%	25.2%	+394.1%	+384.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹133 Cr	₹237 Cr	₹306 Cr	+78.0%
Operating Profit	₹-5 Cr	₹6 Cr	₹33 Cr	+236.6%
OPM %	-3.51%	2.70%	10.80%	+176.9%
NPM %	-1.65%	-1.38%	5.20%	+16.4%
Other Income	₹5 Cr	₹2 Cr	₹3 Cr	-57.3%
Depreciation	₹2 Cr	₹6 Cr	₹9 Cr	+188.2%
Interest	₹0 Cr	₹2 Cr	₹3 Cr	+990.0%
EBIT	₹-7 Cr	₹0 Cr	₹24 Cr	+105.3%
PBT	₹-2 Cr	₹1 Cr	₹24 Cr	+151.4%
Tax	₹-0 Cr	₹5 Cr	₹4 Cr	+1337.5%
Net Profit	₹-2 Cr	₹-3 Cr	₹16 Cr	-48.6%
EPS	₹-0.32	₹-0.52	₹2.94	-62.5%
Material Cost	₹49 Cr	₹87 Cr	₹46 Cr	+76.8%
Employee Cost	₹2 Cr	₹3 Cr	₹2 Cr	+51.8%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	33	43	43	54	+25.6%
Reserves	68	193	191	257	+34.6%
Borrowings	60	77	122	46	-62.3%
Other Liabilities	52	29	45	107	+137.8%
Total Liabilities	213	343	401	464	+15.7%
Fixed Assets	48	50	48	227	+372.9%
CWIP	1	43	156	6	-96.2%
Investments	34	38	0	28	—
Other Assets	130	212	197	202	+2.5%
Total Assets	213	343	401	464	+15.7%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	56	2	1	-10	-1100.0%
Cash from Investing Activity	-55	-144	-53	7	+113.2%
Cash from Financing Activity	-1	152	45	2	-95.6%
Net Cash Flow	-0	10	-7	-1	+85.7%
Free Cash Flow	18	-44	-112	-45	+59.8%
CFO/OP	185%	-11%	25%	-147%	-688.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	97	92	197	144	-26.9%
Inventory Days	17	22	13	84	+546.2%
Days Payable	62	56	128	174	+35.9%
Cash Conversion Cycle	52	57	82	54	-34.1%
Working Capital Days	70	106	156	156	+0.0%
ROCE %	—	-2%	-1%	1%	+200.0%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	74.94%	74.94%	74.94%	74.94%	74.94%	+0.0%
FIIs	0.63%	0.02%	0.01%	0.20%	0.07%	-65.0%
DIIs	0.46%	0.00%	0.00%	0.00%	0.08%	—
Public	23.97%	25.05%	25.05%	24.87%	24.91%	+0.2%
No. of Shareholders	14,432	15,075	14,910	14,657	14,618	-0.3%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	VALIANTLAB Valiant Laboratories	₹123.00	668	41.8	306	16	10.8%	5.2%	78.0%	-48.6%	145.6%	1053.3%

❓ Frequently asked questions

What was Valiant Laboratories Limited's revenue in Q1 FY27?

What was Valiant Laboratories Limited's net profit in Q1 FY27?